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Received December 17, 2012; accepted March 7, 2013AbstractBackground: The microenvironmental biomarkers of different subtypes of ovarian cancers arising from endometriosis have not been studied in
Taiwan. Their expression can help in understanding the carcinogenic mechanism.
Methods: Our study used immunohistochemistry to compare the expression of estrogen receptor (ER), hepatocyte nuclear factor-1 beta (HNF1ß),
p53, phosphatase and tensin homolog (PTEN), BAF250a, and cyclooxygenase-2 (COX-2) among 79 cases of endometriosis-associated ovarian
cancers, including 40 (50%) clear cell carcinomas (CCCs), 33 (41%) endometrioid (EM) adenocarcinomas, four (5%) serous carcinomas, one
adenosquamous carcinoma, and one adenosarcoma.
Results: Positive stainings for ER, HNF1ß, p53, and COX-2 were identified in 34 (43%), 30 (38%), 10 (13%), and 44 (56%) cases. Loss of PTEN
and BAF250a were noted in 29 (37%) and 37 (47%) cases. The expression of ER was reversely correlated with that of HNF1ß (rho ¼ 0.417,
p < 0.001) and correlated with p53 (rho ¼ 0.284, p ¼ 0.011). ER positivity was commonly identified in EM adenocarcinomas (91%), and rarely
in CCCs (8%) and serous carcinoma (0%; p < 0.001). By contrast, HNF1ß expression was frequently noted in CCCs (65%) and serous car-
cinomas (50%), but less in EM adenocarcinoma (6%; p < 0.001). All staining results were similar between atypical endometriosis glandular
epithelium and contiguous malignant parts. Only nine cases showed 10 minor differences (10/474, 2%) in ER, HNF1ß, and BAF250a. For the
staining patterns of p53, COX-2, and PTEN, there was no difference between the invasive and precursor parts.
Conclusion: Our results supported the suggestion that estrogen-dependent ovarian cancer arising from endometriosis is substantially more
associated with EM adenocarcinoma than CCCs. The positive HNF1ß staining was a frequent finding in CCCs, but not in EM adenocarcinoma.
The similar staining patterns of atypical endometriosis glandular cells with the invasive parts confirmed their precursor status.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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2e51. Introduction
Endometriosis is a common gynecologic disease, affecting
approximately 10e15% of women in reproductive years.1
Although endometriosis generally follows a benign course,
its malignant potential and specific association with ovarian* Corresponding author. Dr. Chiung-Ru Lai, Department of Pathology and
Laboratory Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-
Pai Road, Taipei 112, Taiwan, ROC.
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1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.07.008cancer has been documented in prior studies. These
endometriosis-associated ovarian cancers are predominantly
clear cell and endometrioid (EM) histologic subtypes. Van
Gorp et al6 classified ovarian cancer associated with endo-
metriosis into three categories: (1) ovarian cancers with his-
tologic proof of transition from endometriosis to ovarian
cancer, based on the definition of Sampson7 and Scott8; (2)
ovarian cancer with endometriosis in the same ovary, but
without histologic proof of transition; and (3) ovarian cancers
with concomitant endometriosis at any location in the pelvis.
Ovarian cancers arising from endometriosis were onlyhinese Medical Association. All rights reserved.
Table 1
Antibodies used in this study.
Antibodies Clone Source Dilution
ER 6F11 Leica, Newcastle, UK 1:40
HNF1ß Polyclone Proteintech, Chicago, IL, USA 1:200
p53 DO-7 Dako, Glostrup, Denmark 1:50
PTEN 138G6 Cell Signaling, Boston, MA, USA 1:100
BAF250A Polyclone Sigma, St. Louis, MO, USA 1:150
COX-2 4H12 Leica, Newcastle, UK 1:100
COX-2 ¼ cyclooxygenase-2; ER ¼ estrogen receptor; HNF1ß ¼ hepatocyte
nuclear factor-1 beta; N/A ¼ not available; PTEN ¼ phosphatase and tensin
homolog.
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endometriosis-associated ovarian cancers. The frequency of
malignant transformation of endometriosis has been estimated
as 0.7e1.6%,4,9 suggesting that only a small proportion of
endometriosis has the potential to progress into carcinoma.
Recent molecular and pathological evidence suggested that
endometriosis serves as a precursor, and some molecular
events and microenvironmental factors were reported,
including the estrogen effect, hepatocyte nuclear factor-1 beta
(HNF1ß) activation, p53 alteration, phosphatase and tensin
homolog (PTEN) silencing, AT-rich interactive domain 1A
(ARID1A) mutation, and cyclooxygenase-2 (COX-2) over-
expression.10e16 The roles of the above molecular events and
microenvironmental factors in the carcinogenesis of malignant
transformation have never been studied in Taiwan. In the
current study, by using immunohistochemical stains for es-
trogen receptor (ER), HNF1ß, p53, PTEN, BAF250a, and
COX-2, we tried to investigate the relationship of these mo-
lecular alterations and microenvironmental factors among: (1)
the different subtypes of ovarian cancers arising from endo-
metriosis; and (2) the atypical endometriosis glands and the
contiguous invasive areas. The results can provide helpful
information for a better understanding of the carcinogenic
mechanism of these ovarian cancers arising from endometri-
osis in Taiwan.
2. Methods
This is a retrospective study of information obtained from
the archives of the Department of Pathology and Laboratory
Medicine, Taipei Veterans General Hospital, from January
2001 to December 2011. The study was approved by the
hospital administration. After an independent pathological
review by three well-qualified pathologists, a total of 79
consented cases of ovarian cancers arising from endometriosis,
which fulfilled the definition described by Van Gorp et al,6
were included. Of the 79 cases, there were 33 (41%) EM
adenocarcinomas, 40 (50%) clear cell carcinomas (CCC), four
(5%) serous carcinomas, one adenosquamous carcinoma, and
one adenosarcoma. After the histopathological examination,
the paraffin blocks which revealed the continuity of malignant
transformation from endometriosis to cancer, were retrieved.
The immunohistochemical stains for ER, HNF1ß, p53, PTEN,
BAF250a, and COX-2 were performed.
Sections 4 mm thick, from selected formalin-fixed paraffin-
embedded blocks, were assessed by immunohistochemistry.
The antibodies and each dilution used in this study are listed in
Table 1. The sections were stained on an automated system
(BOND-MAX system, Leica, Newcastle, UK) as per the
manufacturer’s protocol, with test and validation sets stained
at different times and the detection kit was Bond (Leica)
Polymer Refine Detection.
The results of the immunohistochemistry were documented
by the percentage of positive cancer cells along with the
staining intensity as: negative; 1þ (focal weakly positive); 3þ
(diffuse strongly positive), and 2þ (in-between). Loss of
PTEN and BAF250a expression was defined as totallynegative staining of the abnormal epithelial cells. The stain-
ings of ER, HNF1ß, and COX-2 were classified as positive
when a staining result over 1þ was found.17,18 For p53, the
presence of diffuse strong nuclear staining has been reported
more specifically to correlate with the presence of Tp53 mu-
tations, so we set 3þ as the relevant cut-off level for p53
staining, similar to the cut-off used in Alkushi et al.19 The
Fisher’s exact test was used for comparisons of categorical
data and the correlation between the expression of these
markers was calculated by Spearman’s rank correlation
coefficient.3. Results
The immunohistochemical profiling for these 79 cases is
summarized in Table 2. ER positive results were more often
identified in EM adenocarcinomas (30/33, 91%) than in CCCs
(3/40, 8%) and serous carcinomas (0/4, 0%). By contrast, the
HNF1ß expression was more often noted in CCCs (26/40,
65%) and serous carcinomas (2/4, 50%) than in EM adeno-
carcinomas (2/33, 6%; Fig. 1). Positive staining for p53 was
more frequently found in serous carcinomas (1/4, 25%) and
EM adenocarcinomas (8/33, 24%) than in CCCs (1/40, 3%). A
loss of PTEN was more often noted in serous carcinomas (4/4,
100%) and EM adenocarcinomas (15/33, 46%) than in CCCs
(9/40, 23%). Positive staining for COX-2 and loss of BAF250a
expression revealed no statistical significance among different
subtypes (Fig. 2). The expression of ER was reversely corre-
lated with that of HNF1ß (Spearman’s rank correlation coef-
ficient rho ¼ 0.417, p < 0.001) and correlated with p53
(rho ¼ 0.284, p ¼ 0.011). The expressions between other
makers had no significant correlation.
The staining results were similar between atypical endo-
metriosis glandular epithelium and contiguous malignant parts
(Fig. 3). Only nine cases showed 10 minor differences in total
474 stains (2%), including ER, HNF1ß, and BAF250a. For the
staining patterns of p53, PTEN, and COX-2, there was no
difference between the invasive and precursor parts (Table 3).4. Discussion
In the current study, we chose ovarian cancers arising from
endometriosis which showed transformation zones from the
atypical endometriosis glands to their contiguous malignant
Table 2
Distribution of staining result by tumor type.
N EM CCC Serous AdenoSq AdenoSa pa
ER (þ) 34 (43) 30 (91) 3 (8) 0 (0) 0 (0) 1 (100) <0.001
HNF1ß (þ) 30 (38) 2 (6) 26 (65) 2 (50) 0 (0) 0 (0) <0.001
p53 (þ) 10 (13) 8 (24) 1 (3) 1 (25) 0 (0) 0 (0) 0.009
PTEN () 29 (37) 15 (46) 9 (23) 4 (100) 1 (100) 0 (0) 0.048
BAF250A () 37 (47) 13 (39) 20 (50) 2 (50) 1 (100) 1 (100) 0.479
COX-2 (þ) 44 (56) 20 (61) 22 (55) 1 (25) 1 (100) 0 (0) 0.644
Total 79 (100) 33 (100) 40 (100) 4 (100) 1 (100) 1 (100)
Data presented as N (%).
AdenoSa ¼ adenosarcoma; AdenoSq ¼ adenosquamous carcinoma; CCC ¼ clear cell carcinoma; EM ¼ endometrioid; Serous ¼ serous carcinoma.
a Fisher’s exact test for EM and CCC.
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PTEN, BAF250a, and COX-2 in both areas of precursors and
invasive parts. ER positivity was often identified in EM ade-
nocarcinomas (91%), whereas HNF1ß expression was
frequently noted in CCCs (65%) and serous carcinomas
(50%). All of the staining results were similar between atyp-
ical endometriosis glandular epithelium and contiguous ma-
lignant parts.
The frequency of the histological types in the current report
is similar to that which has been previously reported.8 CCC
(50%) and EM adenocarcinoma (41%) were common, whereas
other types of ovarian cancers are rarely seen in
endometriosis-associated ovarian cancers. Interestingly, there
was a case of adenosarcoma in our series, but this type of
cancer was not observed in the previous reports. Almost all the
endometriosis associated ovarian cancers were of epithelial
origin and supposed to come from the precursors of atypical
endometriosis. The pathogenesis and the origin of the malig-
nant part of adenosarcoma and sarcoma, rather than carci-
noma, need further study.Fig. 1. Common phenotypic pattern of clear cell carcinomas (CCCs) and endometr
by contiguous transformation of the precursors to the invasive parts (A and D, hema
(ER) is negative in CCC but nearly always positive in EM adenocarcinomas (B and
usually positive in CCC but negative in EM adenocarcinomas (C and F).Although both EM and CCC were commonly seen in the
ovarian cancers arising from endometriosis, their molecular
events are not the same. Unopposed estrogen is associated
with an increased risk of endometrial cancer, and several
studies have suggested that it is also associated with the ma-
lignant transformation of endometriotic cysts.20 Our results
showed ER positivity in 91% of EM adenocarcinomas, but
only in 8% of CCCs and 0% of serous carcinomas. This
revealed that the estrogen effect has a much stronger rela-
tionship to the EM adenocarcinomas, and it played little role
in the carcinogenesis of CCC and serous carcinoma. On the
contrary, HNF1ß was positive in 65% of CCCs but only in 6%
of EM adenocarcinomas. This finding supports the fact that
HNF1ß can be a potential marker for ovarian CCCs.17,21,22
Besides, HNF1ß is also expressed in the precursors, such as
borderline as well as atypical endometriosis, suggesting that
the expression is specifically related to the clear cell lineage,
and is demonstrable at the very early phases of its oncogen-
esis.23 Our results showed no significant difference of the
HNF1ß expression between the atypical endometriosis andioid (EM) adenocarcinomas, arising from ovarian endometriosis, demonstrated
toxylin and eosin staining). Immunohistochemical staining of estrogen receptor
E). On the contrary, the staining of hepatocyte nuclear factor-1 beta (HNF1ß) is
Fig. 2. Examples of immunohistochemical stainings of p53, phosphatase, and tensin homolog (PTEN), BAF250a, and cyclooxygenase-2 (COX-2) in clear cell
carcinomas (CCC) and endometrioid (EM) adenocarcinomas. In CCC, p53 is usually negative but sometimes moderately positive (A); in EM adenocarcinomas,
p53 is often positive (E). Loss of PTEN is a more common finding in EM adenocarcinomas than in CCC (F and B). Complete loss of BAF250a is frequently noted
both in CCC and EM adenocarcinomas (C and G). COX-2 is usually positive both in CCC and EM adenocarcinomas (D and H).
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Mandai et al11 speculated that persistent exposure to oxida-
tive stress and inflammation results in a stress-resistant and
slow-growing phenotype of malignancy, i.e., CCC. To date,Fig. 3. The staining results of hepatocyte nuclear factor-1 beta (HNF1ß) are positiv
glandular epithelium, as well as the contiguous malignant part of clear cell carcinpatients with CCC have a significantly worse prognosis than
patients with non-CCC, because of their low response to
standard platinum-based chemotherapy.22,24 HNF1ß might be
a specific molecular target for the therapy of ovarian CCC ine (A) and of estrogen receptor (ER) are negative (B) in atypical endometriosis
omas (CCC).
Table 3
The staining difference between atypical endometriosis glandular epithelium
(precursor) and contiguous malignant parts.
EM CCC Serous AdenoSq AdenoSa
ER 0 2 0 0 0
HNF1ß 0 2þ, 2 1 0 0
p53 0 0 0 0 0
PTEN 0 0 0 0 0
BAF250A 2þ 1 0 0 0
COX-2 0 0 0 0 0
AdenoSa ¼ adenosarcoma; AdenoSq ¼ adenosquamous carcinoma;
CCC ¼ clear cell carcinoma; EM ¼ endometrioid; Serous ¼ serous carci-
noma; þ ¼ positive in malignant part but negative in precursor area;
 ¼ negative in malignant part but positive in precursor area.
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triosis. Although, 50% (2/4) serous carcinoma cases also
revealed positive HNF1ß staining, the extent of such cells was
no more than 10% of the total cancer cells. In addition, the
case number was too limited to make a conclusion about the
presentation of serous carcinoma. More cases are needed in
future studies.
The tumor suppressor gene p53 was expressed in 13% of
the study cases, a figure less than those in previous reports
(around 40e50%),11 which may be due to different study
cases and criteria to define p53 positivity. Its expression was
more common in EM and serous types of carcinoma than CCC
(24e25% vs. 3%). Our data further concurred with the
existing proposition that alteration in p53 expression may play
a role in malignant transformation of endometriosis, especially
in EM and serous types of carcinoma.
COX-2 is implicated in early events of neoplastic trans-
formation; it is rarely found in normal ovarian surface
epithelia, but is present in endometriosis and in ovarian in-
clusion cysts considered to be premalignant.25 Our previous
report also revealed similar results.26 In the current study, we
further confirmed that COX-2 expression was noted in 56% of
the ovarian carcinomas arising from endometriosis, consistent
with previous studies (42e83% of ovarian cancers). Its
expression had no significance among different subtypes and
no correlations with other markers.
There were PTEN mutations in 20.6% of ovarian endo-
metriotic cysts and 20% of ovarian EM adenocarcinomas re-
ported by Sato et al.27 Our study revealed that considerably
more cases showing PTEN loss were commonly seen in EM
and serous types, than in CCCs (46e100% vs. 23%). Different
study populations and methodologies may explain this
discrepancy, such as the brands of antibodies and the inter-
pretation criteria. More cases are needed for further evaluation
of this phenomenon.
ARID1A mutation, expressed by the loss of the corre-
sponding protein BAF250a, is a newly identified tumor sup-
pressor gene in ovarian clear cell and EM carcinomas. Jones
et al28 found ARID1A mutations in 57% (24/42) of ovarian
CCCs. In Wiegand et al’s report,29 they conducted an ARID1A
mutation analysis in large numbers of ovarian carcinomas and
the mutations were seen in 46% (55/119) of CCC, in 30% (10/
33) of EM adenocarcinomas, and in none of the 76 high-gradeserous carcinomas. However, in another recent study,30 using
tissue microarrays, the loss of BAF250a was also noted in
uterine Grade 3 EM (39%), clear cell (26%), and serous carci-
nomas (18%). In the current study, loss of BAF250awas noted in
47%of cases; its expression had no significance among different
subtypes and no correlations with other markers.
It is increasingly evident that chronic inflammation, coupled
with genetic alteration, promotes the progression of a malignant
endometriosis-associated carcinoma phenotype. Until now, our
study was the first series which conducted this molecular
marker analysis on all cases, with histologic proof of the tran-
sition from endometriosis to ovarian cancer, not just associated
lesions. The staining results were similar between atypical
endometriosis glandular epithelium and contiguous malignant
parts. Only nine cases (9/79, 11%) showed 10 stains (10/474,
2%), with minor differences in ER, HNF1ß, and BAF250a. For
the staining patterns of p53, PTEN, and COX-2, they were
totally identical for the invasive and precursor parts. The above
findings further confirmed the concept that these cancers are
derived from endometriosis and share common molecular and
genetic features between precursors and invasive lesions.
In conclusion, the current Taiwan series study revealed a
similar incidence of the subtypes of ovarian cancers arising
from endometriosis with other previous reports. Many ques-
tions still need to be answered as to the exact pathogenesis of
how endometriotic cysts develop into endometriosis-
associated ovarian carcinomas. However, the possible mech-
anisms and attributing factors, including longstanding unop-
posed estrogen stimulation, repeated incessant menstruation
leading to epithelial damage and repair in an inflammatory
oxidative stress microenvironment, and some early molecular
events, were demonstrated. Whether we can use these bio-
markers as risk factors to help identify high risk endometriosis
or provide information to improve the therapeutic effect, will
be the primary challenges in future studies.References
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